Windlas Biotech Ltd (Windlas) has quietly positioned itself as one of the more interesting mid-cap plays on India’s pharmaceuticals outsourcing wave. The company, headquartered in Dehradun, is ...

Will the return of biotech IPOs become the hottest fashion trend this fall? It’s still early in the season, but Evommune has become the latest indicator that drug developers are once again tempted by ...

The death of William (Bill) Rutter at the grand old age of 97 in July reminded me to remember not only him, but several of the other pioneers of our industry—lest we should forget them. In the late ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. In the past week or so, some initial public offerings ...

Amid a difficult year for federal support of university research, researchers from one of the world’s leading biomedical research institutions gathered to cast their lot with private funders. The ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min As many biotechs face financial ...

LB Pharmaceuticals secured a much-needed US$285m late Wednesday from its upsized Nasdaq IPO, the first US biotech new issue since February. The biotech sold 84.3% of shares outstanding, with more than ...

LB Pharmaceuticals aims to show that what is old can become new again with a lead drug candidate that’s a modified version of a decades-old schizophrenia medication from Sanofi. The strategy is ...

Biopharmaceutical company developing treatment for schizophrenia, bipolar depression, and other neuropsychiatric diseases—LB Pharmaceuticals (LBRX)—raised $285 million in its U.S. IPO, making it the ...

Sept 10 (Reuters) - LB Pharmaceuticals raised $285 million in its U.S. initial public offering, the biotech firm said on Wednesday, marking the first sizable biotech IPO since February. The New ...

BOCA RATON, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it ...